Used in heart-care (coronary) and peripheral procedures, st ents prevent or treat the narrowing and blocking of arteries due to disease or injury . While the use of stents has been largely successful, there are few limitations associated with them. Restenosis, or the reoccur rence of vessel narrowing after stent ing, is a common side effect resulting from the body’s natural response to a foreign object in the blood vessels.
The first generation stents were Bare Metal Stents (BMS) and had a 20 30% higher incidence of in stent re stenosis (ISRs) in the short term.
Some cases also developed thrombosis (clotting). Later, drug-eluting stents (DES) were introduced that delayed stenosis, to overcome the drawbacks of BMS. In 2006, however, a potential safety issue emerged with reports linking DES with the increased risk of late blood clotting. The culprit was thought to be the polymer in the DES which could cause inflammation and could delay vessel healing.
To address this issue and in an end eavor to deliver the best treatment options to patients, alternative ap proaches such as drug-eluting stents with bio-absorbable polymers were developed and have recently hit the market. This stent technology pro vides the best of both worlds to pa tients, where once drug elution is complete; the polymer completely goes away , leaving behind a BMS. The SYNERGY stent system is the only such FDA approved clinically proven solution available today that has ultrathin stent struts with an abluminal bio-absorbable polymer coating technology which is absorbed shortly after drug elution is complete at three months. This helps eliminate longterm polymer exposure.
Dr (Prof) DS Gambhir, group director, Cardiology , Kailash Group of Hospitals, says, “In a very complex group of 100 patients, the SYNERGY Stent showed 0% stent thrombosis at 12 months despite 77% of the patients discontinuing DAPT at 3 months, as revealed during TCT2015.“
According to Dr TS Kler, executive director, Fortis Escorts, “This next generation stent technology is designed with the goal of providing optimal healing for improved patient care, ideal for dealing with complex cases of coronary artery disease.SYNERGY stent’s unique bio-absorbable medicated coating prevents the potential side-effects of long term polymer exposure, thereby providing excellent clinical outcomes. Published studies have also seen chances of recurrence of a clot within the stent in only 0.4% patients.“
Disclaimer: The viewssuggestionsopinions expressed in the article are the sole responsibility of the experts.
Source: Times of India 19 Dec’2015